stockrow
Saturday 7 November 2026
Export NBP’s income statement to Excel — free account
NovaBridge Biosciences
- EPS
- −123.3%
- Free cash flow
- +34.3%
Quarter to June 2026, against a year earlier
0.90
0.01
−1.10%
Follow NBP
Alert me
NovaBridge Biosciences (NBP) EV/Sales
As of 6 November 2026, NovaBridge Biosciences (NBP) trades at a EV/Sales of −5.3×. Over the past ten years it has ranged from −17.5× (February 2020) to 457× (September 2020); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −5.6× | — |
| FY2022 | −0.6× | — |
| FY2021 | 12.4× | (7.68%) |
| FY2020 | 13.4× | — |
| FY2019 | −16.6× | — |
| FY2018 | −16.6× | — |
| FY2017 | −16.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | −14.8× | — |
| Jun 2023 | −6.8× | — |
| Jun 2022 | 1.4× | (88.63%) |
| Dec 2021 | 12.4× | (45.80%) |
| 6 more quarters | Free account |
Against its own ten years
Low −17.5×
High 457×
Ten-year median
−0.8×
Current reading's percentile
23
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. compare | −66.1× |
| NBP NovaBridge Biosciences | −5.3× |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | 0.4× |
| HUMA Humacyte, Inc. compare | 41.4× |
| ANIX ANIXA BIOSCIENCES INC compare | 101× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)